{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T20:55:05Z","timestamp":1769547305191,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Science Center","award":["DEC-2011\/03\/N\/NZ7\/01939"],"award-info":[{"award-number":["DEC-2011\/03\/N\/NZ7\/01939"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.toxlet.2013.10.035","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T09:34:41Z","timestamp":1383644081000},"page":"225-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells"],"prefix":"10.1016","volume":"224","author":[{"given":"Patrycja","family":"Kwieci\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Taub\u00f8ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa \u0141ucja","family":"Gregoraszczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2013.10.035_bib0005","doi-asserted-by":"crossref","first-page":"51218","DOI":"10.1074\/jbc.M409271200","article-title":"Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis","volume":"279","author":"Bakin","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noq044","article-title":"Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide","volume":"12","author":"Bobustuc","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2119\/2007-00084.Bokelmann","article-title":"Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins","volume":"14","author":"Bokelmann","year":"2008","journal-title":"Mol. Med."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.brainresbull.2005.01.004","article-title":"Microarray analysis of rat brain gene expression after chronic administration of sodium valproate","volume":"65","author":"Bosetti","year":"2005","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0025","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1083\/jcb.100.4.1284","article-title":"Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells","volume":"100","author":"Buckley","year":"1985","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0030","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"Candelaria","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-4-22","article-title":"Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study","volume":"4","author":"Chavez-Blanco","year":"2005","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1528-1157.2003.25302.x","article-title":"Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid","volume":"44","author":"Coupez","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0045","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","article-title":"Valproate induces replication independent active DNA demethylation","volume":"278","author":"Detich","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0050","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/1535-7163.MCT-07-0251","article-title":"Histone deacetylase inhibitors selectively suppress expression of HDAC7","volume":"6","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0055","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1158\/1541-7786.MCR-08-0299","article-title":"Specific activity of class II histone deacetylases in human breast cancer cells","volume":"6","author":"Duong","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0060","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.0013-9580.2004.00104.x","article-title":"The activity of antiepileptic drugs as histone deacetylase inhibitors","volume":"45","author":"Eyal","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0065","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.humpath.2009.11.012","article-title":"Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells","volume":"41","author":"Fakhry","year":"2010","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0070","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/excr.2000.5080","article-title":"The human histone deacetylase family","volume":"262","author":"Gray","year":"2001","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0080","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0085","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","article-title":"Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells","volume":"5","author":"Hrzenjak","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0090","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","article-title":"Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1","volume":"12","author":"Huang","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0095","first-page":"225","article-title":"Cancer statistics","volume":"59","author":"Jemal","year":"2009","journal-title":"CA: Cancer J. Clin."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3802\/jgo.2008.19.3.185","article-title":"Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues","volume":"19","author":"Jin","year":"2008","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0110","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo","volume":"13","author":"Jones","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4161\/cbt.6.5.4007","article-title":"Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy","volume":"6","author":"Khabele","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3802\/jgo.2012.23.3.182","article-title":"The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines","volume":"23","author":"Kim","year":"2012","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0125","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Kr\u00e4mer","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1734-1140(12)70742-9","article-title":"Effects of valproic acid and levetiracetam on viability and cell cycle regulatory genes expression in the OVCAR-3 cell line","volume":"64","author":"Kwieci\u0144ska","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0135","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1734-1140(12)70856-3","article-title":"Comparison of the effects of valproic acid and levetiracetam on apoptosis in the human ovarian cancer cell line OVCAR-3","volume":"64","author":"Kwieci\u0144ska","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0140","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1535-7163.MCT-05-0184","article-title":"Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC","volume":"4","author":"Li","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0145","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1349-7006.2008.00793.x","article-title":"Valproic acid resensitizes cisplatin-resistant ovarian cancer cells","volume":"99","author":"Lin","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0150","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0155","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0160","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1471-4892(03)00084-5","article-title":"Histone deacetylases","volume":"3","author":"Marks","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0170","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"Gynecologic oncology group, a phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0175","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08301.x","article-title":"Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia","volume":"150","author":"Moreno","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0180","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1161\/CIRCRESAHA.107.149377","article-title":"Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis","volume":"101","author":"Mottet","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ijc.20395","article-title":"Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients","volume":"112","author":"Osada","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0190","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1245\/s10434-008-9940-z","article-title":"High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas","volume":"15","author":"Oua\u00efssi","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0195","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2164-7-90","article-title":"Differential expression of selected histone modifier genes in human solid cancers","volume":"7","author":"Ozda\u011f","year":"2006","journal-title":"BMC Genomics"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0205","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0210","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0002-9440(10)64645-7","article-title":"Synaptic vesicle protein 2, a new neuroendocrine cell marker","volume":"157","author":"Portela-Gomes","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00428-011-1103-0","article-title":"Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC","volume":"459","author":"Quint","year":"2011","journal-title":"Virchows Arch."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0220","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1593\/tlo.08136","article-title":"A phase II clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy","volume":"1","author":"Sharma","year":"2008","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0225","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","article-title":"Increased expression of histone deacetylase 2 is found in human gastric cancer","volume":"113","author":"Song","year":"2005","journal-title":"APMIS"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CEJ.0b013e32834a7e6f","article-title":"Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer","volume":"21","author":"Stettner","year":"2012","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0240","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.20709","article-title":"Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis","volume":"101","author":"Takai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.toxlet.2013.10.035_bib0245","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biocel.2008.08.019","article-title":"Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status","volume":"41","author":"Travaglini","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.toxlet.2013.10.035_bib0250","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00109-010-0701-7","article-title":"The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc","volume":"89","author":"Zhu","year":"2011","journal-title":"J. Mol. Med. (Berl)"}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427413013878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427413013878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T01:54:14Z","timestamp":1539222854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427413013878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0378427413013878"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2013.10.035","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2013.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}